PepGen (NASDAQ:PEPG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PepGen (NASDAQ:PEPG – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, PepGen has a consensus rating of “Moderate Buy” and an average price target of $11.40.

View Our Latest Stock Analysis on PepGen

PepGen Stock Performance

PEPG opened at $2.39 on Friday. The business’s 50-day simple moving average is $2.66 and its 200 day simple moving average is $2.98. PepGen has a 52-week low of $1.31 and a 52-week high of $7.80. The firm has a market capitalization of $165.53 million, a PE ratio of -1.82 and a beta of 2.02.

Hedge Funds Weigh In On PepGen

Institutional investors have recently bought and sold shares of the business. Brendel Financial Advisors LLC acquired a new position in shares of PepGen during the 3rd quarter worth approximately $306,000. Squarepoint Ops LLC raised its stake in PepGen by 260.9% in the 2nd quarter. Squarepoint Ops LLC now owns 529,083 shares of the company’s stock valued at $952,000 after acquiring an additional 382,487 shares during the period. Artia Global Partners LP bought a new stake in PepGen in the 2nd quarter valued at $370,000. AWM Investment Company Inc. bought a new stake in PepGen in the 2nd quarter valued at $1,080,000. Finally, ADAR1 Capital Management LLC acquired a new stake in PepGen during the 2nd quarter valued at $4,664,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

(Get Free Report)

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.

See Also

Analyst Recommendations for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.